Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is advancing a novel synthetic lethal and immune activating pipeline. Leading its portfolio, Volastra has two KIF18A inhibitors in Phase 1 clinical trials for cancers with high levels of chromosomal instability.
Company Details
- Employees
- 44
- Founded
- -
- Address
- 1361 Amsterdam Ave,
- Industry
- Biotechnology
- Website
- volastratx.com
- HQ
- New York, New York
Volastra Therapeutics Questions
Volastra Therapeutics's website is volastratx.com
Volastra Therapeutics's LinkedIn profile is https://www.linkedin.com/company/volastra-therapeutics
Volastra Therapeutics has
44 employees.
View email and phone details for 44
employees at Volastra Therapeutics.
Volastra Therapeutics's industry is
Biotechnology
Volastra Therapeutics's top competitors are
Nilo Therapeutics,
Ampersand Biomedicines,
Tessera Therapeutics,
Noema Pharma,
Rapport Therapeutics,
Bluerock Therapeutics,
Lexeo Therapeutics,
Regeneron,
Eikon Therapeutics,
Aethon Therapeutics.
Volastra Therapeutics's categories are Biotechnology
Volastra Therapeutics's founding year is 2019
